← Ultragenyx Pharmaceutical Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $133k |
$2.6m
+1863.91%
|
$51.5m
+1871.48%
|
$103.7m
+101.41%
|
$271.0m
+161.32%
|
$351.4m
+29.66%
|
$363.3m
+3.39%
|
$434.2m
+19.52%
|
$560.2m
+29.01%
|
$673.0m
+20.13%
|
$717.0m
+6.54%
|
|
| Cost of Revenue | $183.2m |
$1k
-100.00%
|
$1.1m
+114500.00%
|
$366.4m
+31868.85%
|
$418.2m
+14.15%
|
$513.2m
+22.70%
|
$734.1m
+43.06%
|
$693.7m
-5.51%
|
$774.6m
+11.67%
|
$859.0m
+10.90%
|
$121.0m
-85.91%
|
|
| Gross Profit (Calculated) (derived) | ($183.1m) |
$2.6m
+101.43%
|
$50.3m
+1828.34%
|
($262.6m)
-621.66%
|
($147.2m)
+43.96%
|
($161.8m)
-9.90%
|
($370.8m)
-129.22%
|
($259.4m)
+30.04%
|
($214.4m)
+17.36%
|
($186.0m)
+13.23%
|
— | |
| Research and Development Expense | $183.2m | $231.6m | $294.0m | $357.4m | $412.1m | $497.2m | $705.8m | $648.4m | $697.9m | $750.0m | $773.0m | |
| General and Administrative Expense | $64.9m | $99.9m | $127.7m | $161.5m | $182.9m | $220.0m | $278.1m | $309.8m | $321.6m | $349.0m | — | |
| Operating Expenses | $248.1m | $331.6m | $422.9m | $527.9m | $601.1m | — | — | — | — | — | $1.2b | |
| Operating Income (Loss) | ($248.0m) |
($328.9m)
-32.63%
|
($371.4m)
-12.90%
|
($424.2m)
-14.22%
|
($330.1m)
+22.17%
|
($381.7m)
-15.64%
|
($648.9m)
-69.99%
|
($569.2m)
+12.28%
|
($536.0m)
+5.84%
|
($535.0m)
+0.18%
|
($528.0m)
+1.31%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | ($1.3m) | $7.0m | ($5.3m) | ($688k) | $221k | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($1.6m) | $6.5m | ($5.6m) | ($787k) | $607k | ($1.7m) | ($1.6m) | ($337k) | ($4.0m) | $1.0m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($192.3m) | ($250.9m) | ($205.4m) | ($399.7m) | ($189.4m) | ($455.3m) | ($703.4m) | ($608.2m) | ($564.1m) | ($565.0m) | ($582.0m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($245.8m) | ($318.3m) | ($197.1m) | ($399.4m) | ($185.4m) | ($453.0m) | ($701.7m) | ($608.5m) | ($567.6m) | ($571.0m) | ($582.0m) | |
| Current Income Tax Expense (Benefit) | — | $47k | $514k | $1.1m | $1.2m | $1.0m | $7.3m | ($60k) | $3.0m | $4.0m | $4.0m | |
| Income Tax Expense (Benefit) | $35k | ($16.2m) | $514k | $3.3m | $1.2m | $1.0m | $5.7m | ($1.8m) | $1.6m | $4.0m | $4.0m | |
| Net Income (Loss) Attributable to Parent | ($245.9m) |
($302.1m)
-22.88%
|
($197.6m)
+34.60%
|
($402.7m)
-103.80%
|
($186.6m)
+53.67%
|
($454.0m)
-143.36%
|
($707.4m)
-55.81%
|
($606.6m)
+14.25%
|
($569.2m)
+6.17%
|
($575.0m)
-1.02%
|
($586.0m)
-1.91%
|
|
| Earnings Per Share, Basic | — | — | — | — | ($3.07) | ($6.70) | ($10.12) | ($8.25) | ($6.29) | ($5.83) | ($5.83) | |
| Earnings Per Share, Diluted | — | — | — | — | ($3.07) | ($6.70) | ($10.12) | ($8.25) | ($6.29) | ($5.83) | ($5.83) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | — | 69.9m | 73.5m | 90.5m | 98.6m | 100.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | — | 69.9m | 73.5m | 90.5m | 98.6m | 100.5m |